A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome

被引:21
|
作者
Dean, Diana J. [1 ,2 ]
Sabagha, Noor [1 ]
Rose, Kaitlin [1 ,3 ]
Weiss, Alexander [1 ]
France, John [4 ]
Asmar, Timothy [1 ]
Rammal, Jo-Ann [1 ]
Beyer, Margaret [1 ]
Bussa, Rebecca [1 ]
Ross, Jacob [1 ]
Chaudhry, Kaleem [1 ]
Smoot, Thomas [5 ]
Wilson, Kathleen [1 ]
Miller, Joseph [1 ,4 ]
机构
[1] Henry Ford Hosp, Dept Emergency Med, Detroit, MI 48202 USA
[2] Michigan Poison Ctr, Detroit, MI USA
[3] Cent Michigan Univ, Coll Med, Mt Pleasant, MI 48859 USA
[4] Wayne State Univ, Detroit, MI 48202 USA
[5] Frederick Mem Hosp, Frederick, MD USA
关键词
EMERGENCY-DEPARTMENT; OSTEOARTHRITIS; SEVERITY; EFFICACY; NAUSEA;
D O I
10.1111/acem.14062
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives Patients with cannabinoid hyperemesis syndrome (CHS) present frequently to the emergency department. Previous case studies suggest dramatic symptomatic improvement with topical capsaicin treatment. This exploratory study examined the potential effectiveness of topical capsaicin in patients with nausea and vomiting due to a suspected CHS exacerbation. Methods This was a double-blind, randomized placebo-controlled pilot trial. Adults who presented with vomiting suspected to be from CHS were eligible for enrollment. We excluded pregnant women and those with resolution of symptoms. Following randomization, topical 0.1% capsaicin or placebo cream was applied to the anterior abdomen in a uniform manner. The primary outcome was the severity of nausea on a visual analog scale (VAS) of 0 to 10 cm assessed at 30 minutes. Secondary outcomes were adverse events, occurrence of posttreatment vomiting, nausea by VAS at 60 minutes, and hospital admission. Results This pilot trial enrolled 30 patients, 17 in the capsaicin arm and 13 in the placebo arm. One patient in the capsaicin arm did not tolerate treatment due to skin irritation. Mean +/- SD nausea severity at 30 minutes was 4.1 +/- 2.3 cm in the capsaicin arm and 6.1 +/- 3.3 cm in the placebo arm (difference = -2.0 cm, 95% confidence interval [CI] = 0.2 to -4.2 cm). At 60 minutes, mean +/- SD nausea severity was 3.2 +/- 3.2 cm versus 6.4 +/- 2.8 cm (difference = -3.2 cm, 95% CI = -0.9 to -5.4 cm). The percent reduction in nausea at 60 minutes from baseline was 46.0% in the capsaicin arm and 24.9% in the placebo arm (difference = 21.1%, 95% CI = -5.6% to 47.9%). A higher proportion of capsaicin group patients (29.4% vs. 0%) had complete resolution of nausea (relative risk = 3.4, 95% CI = 1.6 to 7.1). Conclusion In this pilot trial, the application of topical capsaicin cream was associated with a significant reduction in nausea at 60 minutes but not at 30 minutes and provided more complete relief of nausea.
引用
收藏
页码:1166 / 1172
页数:7
相关论文
共 50 条
  • [21] Cannabinoid hyperemesis syndrome and topical capsaicin: treating smoke with fire? - the authors reply
    Hafez, Zachary
    Mullins, Michael E.
    Blohm, Eike
    O'Connor, Mark J.
    Dezieck, Laurel
    Schwarz, Evan S.
    Conicella, Albert
    CLINICAL TOXICOLOGY, 2018, 56 (01) : 79 - 79
  • [22] Efficacy of Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review
    McConachie, Sean M.
    Caputo, Ryan A.
    Wilhelm, Sheila M.
    Kale-Pradhan, Pramodini B.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (11) : 1145 - 1152
  • [23] USE OF CAPSAICIN CREAM IN CANNABIS HYPEREMESIS SYNDROME
    Burillo-Putze, Guillermo
    Llorens, Pere
    Roman, Francisco
    JOURNAL OF EMERGENCY MEDICINE, 2017, 52 (05): : 760 - 760
  • [24] Management of Cannabinoid Hyperemesis Syndrome: Focus on Capsaicin
    Stumpf, Janice L.
    Williams, Lauren D.
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (05) : 786 - 793
  • [25] Authors' response to "Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department"
    Wagner, Samantha
    Hoppe, Jason
    Zuckerman, Matthew
    Schwarz, Kerry
    McLaughlin, Julie
    CLINICAL TOXICOLOGY, 2020, 58 (09) : 939 - 939
  • [26] Capsaicin topical cream (8%) for the treatment of myofascial pain syndrome
    Romero, Valeria
    Lara, Juliana Rodrigues
    Otero-Espinar, Francisco
    Salgado, Manoel Henrique
    Pinheiro Modolo, Norma Sueli
    Moreira de Barros, Guilherme Antonio
    REVISTA BRASILEIRA DE ANESTESIOLOGIA, 2019, 69 (05): : 432 - 438
  • [27] Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment
    Richards, John R.
    Lapoint, Jeff M.
    Burillo-Putze, Guillermo
    CLINICAL TOXICOLOGY, 2018, 56 (01) : 15 - 24
  • [28] Haloperidol for treatment of cannabinoid hyperemesis syndrome
    Hickey, Jami L.
    Witsil, Joanne C.
    Mycyk, Mark B.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2013, 31 (06): : 1003.e5 - 1003.e6
  • [29] The diagnosis and treatment of cannabinoid hyperemesis syndrome
    Misa Garcia, Aron
    Medina Guerrero, Alvaro
    Fages Perez, Marina
    Ibanez Borau, Yolanda
    Calderon Hernanz, Beatriz
    Vilanova Bolto, Montserrat
    Agudo Garcia, Miguel
    CLINICAL TOXICOLOGY, 2023, 61 : 15 - 15
  • [30] Perspectives in the treatment for cannabinoid hyperemesis syndrome
    Burillo-Putze, Guillermo
    Llorens, Pere
    ADICCIONES, 2017, 29 (02) : 134 - 135